重组人生长激素治疗难治性阴茎勃起功能障碍伴胰岛素样生长因子-1低下的临床观察  

Recombinant Human Growth Hormone in Refractory Erectile Dysfunction with Low Insulin-like Growth Factor-1

作　　者：余志勇 熊滕仙 童旭先 陈明根 罗龙华[1] 周嘉明 孙翔[1] YU Zhi-yong;XIONG Teng-xian;TONG Xu-xian;CHEN Ming-gen;LUO Long-hua;ZHOU Jia-ming;SUN Xiang(Department of Urology,the First Affiliated Hospital of Nanchang University,Nanchang 330006,China;Department of Urology,Gaoxin District Hospital,the First Affiliated Hospital of Nanchang University,Nanchang 330096,China)

机构地区：[1]南昌大学第一附属医院泌尿外科,南昌330006 [2]南昌大学第一附属医院高新医院泌尿外科,南昌330096

出　　处：《实用临床医学（江西）》2024年第3期20-23,共4页Practical Clinical Medicine

基　　金：江西省卫健委科技计划项目(202310234);南昌市科技支撑计划项目(2020KJZCHTS-22)。

摘　　要：目的 观察重组人生长激素治疗难治性阴茎勃起功能障碍(ED)伴胰岛素样生长因子-1(IGF-1)低下的临床效果。方法 选取2022年6月至2023年2月泌尿外科和男科门诊收治的19例难治性ED伴IGF-1低下的患者,年龄25~65岁。给予重组人生长激素(2U,睡前腹壁皮下注射,每周一、周四各1次)。分别在治疗前、治疗第1和第3个月记录国际勃起功能指数问卷5(IIEF-5)评分,性生活日志(SEP)中的问题2和3(SEP2、SEP3)。同时监测患者治疗前和治疗第3个月的肝肾功能、血糖、血脂、睾酮、IGF-1、前列腺特异性抗原(PSA)的变化,记录治疗过程中发生的不良反应。结果 共19例患者入组研究并完成随访。治疗第3个月IIEF-5评分为(11.63±2.81)分,高于治疗前的(7.53±2.75)分(P<0.05)。治疗第3个月患者总有效率为68.4%(13/19)。SEP2/3回答“能”:治疗前均为0%,治疗第1和3个月分别为15.8%/5.3%、42.1%/26.3%。治疗后血液指标IGF-1高于治疗前(P<0.05),其他相关指标比较差异无统计学意义(P>0.05)。治疗过程中,不良反应发生率为21.1%((4/19)),未经特殊处理均自行缓解。结论 重组人生长激素能改善难治性ED伴IGF-1低下患者的症状评分,且治疗有效率较高。Objective To observe clinical efficacy of recombinant human growth hormone in the treatment of patients with refractory penile erectile dysfunction(ED)accompanied with low insulin-like growth factor-1(IGF-1).Methods A total of 19 patients with refractory ED with low IGF-1,aged from 25 to 65 years,were selected from the Urology and Andrology Outpatients of our hospital from June 2022 to February 2023.All the subjects were injected with recombinant human growth hormone(2U,subcutaneously into the abdominal wall at bedtime,once a week on Mondays and Thursdays).The International Index of Erectile Function Questionnaire 5(IIEF-5)scores,Questions 2 and 3 in the Sexual Life Log(SEP)were recorded before treatment,at months 1 and 3 of treatment,respectively.Patients were also monitored for changes in liver and kidney functions,blood glucose,blood lipid,testosterone,IGF-1,and prostate-specific antigen(PSA)before treatment and in the 3rd month of treatment,and adverse reactions that occurred during treatment were recorded.Results All the 19 patients enrolled in the study completed follow-up visits.The IIEF-5 scores at the 3rd month of treatment were 11.63±2.81,higher than the pre-treatment scores(7.53±2.75)(P<0.05);the overall response rate at the 3rd month of treatment was 68.4%(13/19).The answers“yes”to SEP2/3 were 0%before treatment,15.8%/5.3%after 1 month and 42.1%/26.3%after 3 months.The blood index IGF-1 after treatment was higher than that before treatment(P<0.05),and the difference of other related indexes was not statistically significant(P>0.05).During the treatment,the incidence rate of adverse reactions was 21.1%(4/19),which were all alleviated on their own without special interventions.ConclusionRecombinant human growth hormone can alleviate clinical symptoms and bring a favorable response rate in patients with refractory ED with low IGF-1.

关 键 词：难治性阴茎勃起功能障碍 胰岛素样生长因子-1 生长激素 

分 类 号：R699.8[医药卫生—泌尿科学]